Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of
myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined
list. The list includes 65 p53 mutations that were experimentally confirmed to be
pharmacologically restored with tumor-suppressive function by antimonials.